Clinical Trial Update: Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) [Phase 4]

View source ↗

Summary

Pfizer's Phase 4 post-trial access study for Elranatamab in participants with multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 4 | Status: RECRUITING